IGF2BP2 read m6A modifications on circQSOX1 and promoted CRC progression and immune escape through the miR-326/miR-330–5p/PGAM1 axis, which compromised anti-CTLA-4 therapy in CRC patients [98]. Here, IGF2BP2 is linked to colorectal carcinoma.